JP2006528199A5 - - Google Patents

Download PDF

Info

Publication number
JP2006528199A5
JP2006528199A5 JP2006521248A JP2006521248A JP2006528199A5 JP 2006528199 A5 JP2006528199 A5 JP 2006528199A5 JP 2006521248 A JP2006521248 A JP 2006521248A JP 2006521248 A JP2006521248 A JP 2006521248A JP 2006528199 A5 JP2006528199 A5 JP 2006528199A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
ethyl
composition according
formula
purine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006521248A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006528199A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/023632 external-priority patent/WO2005009445A1/en
Publication of JP2006528199A publication Critical patent/JP2006528199A/ja
Publication of JP2006528199A5 publication Critical patent/JP2006528199A5/ja
Pending legal-status Critical Current

Links

JP2006521248A 2003-07-22 2004-07-22 A1アデノシン受容体拮抗薬 Pending JP2006528199A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48946903P 2003-07-22 2003-07-22
PCT/US2004/023632 WO2005009445A1 (en) 2003-07-22 2004-07-22 A1 adenosine receptor antagonists

Publications (2)

Publication Number Publication Date
JP2006528199A JP2006528199A (ja) 2006-12-14
JP2006528199A5 true JP2006528199A5 (enExample) 2007-08-02

Family

ID=34102883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006521248A Pending JP2006528199A (ja) 2003-07-22 2004-07-22 A1アデノシン受容体拮抗薬

Country Status (8)

Country Link
US (1) US7022710B2 (enExample)
EP (1) EP1646390B1 (enExample)
JP (1) JP2006528199A (enExample)
KR (1) KR20060037383A (enExample)
AT (1) ATE410168T1 (enExample)
CA (1) CA2533402A1 (enExample)
DE (1) DE602004017005D1 (enExample)
WO (1) WO2005009445A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005047268A2 (en) * 2003-11-10 2005-05-26 X-Ceptor Therapeutics, Inc. Substituted pyrimidine compositions and methods of use
US20080280926A1 (en) * 2003-12-16 2008-11-13 Palle Venkata P Phosphodiesterase Inhibitors
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
ES2361886T3 (es) * 2006-06-27 2011-06-24 Cbt Development Limited Profármacos adenosina acetil 2',3'-metilideno novedosos para uso como profármacos para agonistas del receptor adenosina.
WO2009052310A1 (en) * 2007-10-16 2009-04-23 Cv Therapeutics, Inc A3 adenosine receptor antagonists
BRPI0909157A2 (pt) * 2008-03-26 2015-11-24 Advinus Therapeutics Private Ltd compostos heterocíclicos como antagonistas de receptores de adenosina
DE102008039083A1 (de) * 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
WO2024105159A1 (en) * 2022-11-16 2024-05-23 University Of Zurich Ligands of the m6a-rna readers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
DK1208100T3 (da) * 1999-08-31 2003-06-30 Univ Vanderbilt Selektive antagonister af A2B adenosinreceptorer
KR20020042248A (ko) * 2000-11-30 2002-06-05 한가람 문장으로부터의 감정 인식 및 표시 방법과 시스템
EP1401837B1 (en) * 2001-06-29 2005-10-19 Cv Therapeutics, Inc. Purine derivatives as a2b adenosine receptor antagonists
WO2003006465A1 (en) * 2001-07-13 2003-01-23 Cv Therapeutics, Inc. Partial and full agonist of a adenosine receptors
US7968523B2 (en) 2001-07-23 2011-06-28 Senesco Technologies, Inc. Method for inducing apoptosis using apoptosis-specific EIF5-A
AU2002361374A1 (en) * 2001-12-21 2003-07-09 JSW-Research Forschungslabor GmbH% Pyrazolyl-substituted triazoloquinoxalines

Similar Documents

Publication Publication Date Title
JP2019031560A5 (enExample)
JP2006528199A5 (enExample)
JP2015520738A5 (enExample)
JP2012519179A5 (enExample)
JP2011509309A5 (enExample)
JP2017528506A5 (enExample)
RU2019120990A (ru) Бициклические гетероарильные производные в качестве стимуляторов cftr
JP2004523535A5 (enExample)
JP2019514945A5 (enExample)
JP2001525412A (ja) Pdeiv阻害活性を有するプリン化合物および合成方法
JP2014526500A5 (enExample)
JP2010501478A5 (enExample)
JP2004517049A5 (enExample)
WO2005087729A1 (en) 5-hydroxyindole-3-carboxylates derivatives and their use
JP2004513882A5 (enExample)
JP2006501201A5 (enExample)
JP2011504935A5 (enExample)
CN102762542A (zh) 一种新型抗真菌三唑衍生物
JP2008543860A5 (enExample)
JP2006507355A5 (enExample)
JP2002540102A (ja) cGMPホスホジエステラーゼの縮合ピリドピリダジン阻害剤
JP2011516498A5 (enExample)
JP2013508382A5 (enExample)
WO2008117229A4 (en) Muscarinic receptor antagonists
JP2017522348A5 (enExample)